NCT07164469View on ClinicalTrials.gov

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

February 28, 2026

Primary Completion Date

September 30, 2031

Study Completion Date

September 30, 2033

Conditions

Large B-cell LymphomaHodgkin Lymphoma

Interventions

DRUG

Fludarabine

Given by IV

DRUG

Cyclophosphamide

Given by IV

DRUG

CD70.CAR NK Cells

Given by IV Infusion

DRUG

Rimiducid (AP1903)

Given by IV Infusion

Trial Locations (1)

77030

The University of Texas M. D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Bellicum Pharmaceuticals

All Listed Sponsors

collaborator

Bellicum Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER